CSL Limited
(ASX:CSL) has closed a new private placement in the US, valued at $US500 million.
CFO Gordon Naylor says the placement has enabled CSL to significantly strengthen its debt maturity profile at very attractive long term interest rates.
Mr Naylor says the placement was well received by investors, and is recognition of the sustainability of CSL’s business model.
Proceeds from the private placement will be used to fund the biopharmaceutical company’s capital management plan and for general corporate purposes.
CSL generated a net profit of $603.7 million in the first half of fiscal 2013.
